These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
233 related articles for article (PubMed ID: 32924697)
21. The Frequency of Medication-related Osteonecrosis of the Jaw and its Associated Risk Factors. Dodson TB Oral Maxillofac Surg Clin North Am; 2015 Nov; 27(4):509-16. PubMed ID: 26362367 [TBL] [Abstract][Full Text] [Related]
23. Microarchitecture of medication-related osteonecrosis of the jaw (MRONJ); a retrospective micro-CT and morphometric analysis. Schoenhof R; Munz A; Yuan A; ElAyouti A; Boesmueller H; Blumenstock G; Reinert S; Hoefert S J Craniomaxillofac Surg; 2021 Jun; 49(6):508-517. PubMed ID: 33707134 [TBL] [Abstract][Full Text] [Related]
24. Surgical therapy for medication-related osteonecrosis of the jaw in osteoporotic patients treated with antiresorptive agents. Hauer L; Jambura J; Hrusak D; Chalupova M; Posta P; Rusnak S; Vyskocil V Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2020 Mar; 164(1):100-107. PubMed ID: 30647474 [TBL] [Abstract][Full Text] [Related]
25. Medication-Related Osteonecrosis of the Jaws and CDK4/6 Inhibitors: A Recent Association. Marcianò A; Guzzo GM; Peditto M; Picone A; Oteri G Int J Environ Res Public Health; 2020 Dec; 17(24):. PubMed ID: 33353034 [TBL] [Abstract][Full Text] [Related]
26. Database analysis of the risk factors of bisphosphonate-related osteonecrosis of the jaw in Hungarian patients. Veszelyné Kotán E; Bartha-Lieb T; Parisek Z; Meskó A; Vaszilkó M; Hankó B BMJ Open; 2019 May; 9(5):e025600. PubMed ID: 31122970 [TBL] [Abstract][Full Text] [Related]
27. Knowledge and attitude regarding bisphosphonates and related osteonecrosis among Turkish dentist: A cross sectional study. Ozkan E; Bereket MC; Ozkan N Niger J Clin Pract; 2021 Oct; 24(10):1485-1491. PubMed ID: 34657014 [TBL] [Abstract][Full Text] [Related]
28. Medication-Related Osteonecrosis of the Jaw: A Cross-Sectional Study on the Prevalence of Cutaneous Manifestations and the Primary Care Physician's Role in its Early Diagnosis. Whitefield S; Ilan MB; Lazarovici TS; Friedlander-Barenboim S; Kassem R; Yarom N Am J Med; 2024 Mar; 137(3):266-272. PubMed ID: 38042241 [TBL] [Abstract][Full Text] [Related]
29. Factors affecting development of medication-related osteonecrosis of the jaw in cancer patients receiving high-dose bisphosphonate or denosumab therapy: Is tooth extraction a risk factor? Soutome S; Hayashida S; Funahara M; Sakamoto Y; Kojima Y; Yanamoto S; Umeda M PLoS One; 2018; 13(7):e0201343. PubMed ID: 30048523 [TBL] [Abstract][Full Text] [Related]
30. Awareness among patient at risk of developing Medication Related Osteonecrosis of the Jaw (MRONJ) - A primary prevention strategy. Al Abdullateef A; Alhareky MS Saudi Pharm J; 2020 Jun; 28(6):771-778. PubMed ID: 32550810 [TBL] [Abstract][Full Text] [Related]
31. Clinical values of serum Semaphorin 4D (Sema4D) in medication‑related osteonecrosis of the jaw. Mu H; Pang Y; Liu L; Liu J; Liu C Eur J Med Res; 2023 Mar; 28(1):140. PubMed ID: 36998031 [TBL] [Abstract][Full Text] [Related]
32. Survey of Korean dentists on the awareness on bisphosphonate-related osteonecrosis of the jaws. Yoo JY; Park YD; Kwon YD; Kim DY; Ohe JY J Investig Clin Dent; 2010 Nov; 1(2):90-5. PubMed ID: 25427263 [TBL] [Abstract][Full Text] [Related]
33. Cooperation between physicians and dentists for osteonecrosis of the jaw: a 2022 Japanese survey. Taguchi A; Hagino H; Inoue D; Endo N; Society JO J Bone Miner Metab; 2023 Nov; 41(6):829-837. PubMed ID: 37516668 [TBL] [Abstract][Full Text] [Related]
34. Use of oral bisphosphonates and risk of hospital admission with osteonecrosis of the jaw: Large prospective cohort study in UK women. Wotton CJ; Green J; Brown A; Armstrong MEG; Floud S; Beral V; Reeves GK; Bone; 2019 Jul; 124():69-74. PubMed ID: 30959190 [TBL] [Abstract][Full Text] [Related]
35. The Prevention of Medication-related Osteonecrosis of the Jaw. Poxleitner P; Engelhardt M; Schmelzeisen R; Voss P Dtsch Arztebl Int; 2017 Feb; 114(5):63-69. PubMed ID: 28241916 [TBL] [Abstract][Full Text] [Related]
36. Declining Incidence of Medication-Related Osteonecrosis of the Jaw in Patients With Cancer. Sim IeW; Sanders KM; Borromeo GL; Seymour JF; Ebeling PR J Clin Endocrinol Metab; 2015 Oct; 100(10):3887-93. PubMed ID: 26241323 [TBL] [Abstract][Full Text] [Related]
37. The awareness and practice of dentists regarding medication-related osteonecrosis of the jaw and its prevention: a cross-sectional survey. Han AL BMC Oral Health; 2021 Mar; 21(1):155. PubMed ID: 33761923 [TBL] [Abstract][Full Text] [Related]
38. Choosing the Right Partner for Medication Related Osteonecrosis of the Jaw: What Central European Dentists Know. Bruckmoser E; Palaoro M; Latzko L; Schnabl D; Neururer SB; Laimer J Int J Environ Res Public Health; 2021 Apr; 18(9):. PubMed ID: 33922326 [TBL] [Abstract][Full Text] [Related]
39. Medication-related osteonecrosis of the jaw: An update on the memorial sloan kettering cancer center experience and the role of premedication dental evaluation in prevention. Owosho AA; Liang STY; Sax AZ; Wu K; Yom SK; Huryn JM; Estilo CL Oral Surg Oral Med Oral Pathol Oral Radiol; 2018 May; 125(5):440-445. PubMed ID: 29580668 [TBL] [Abstract][Full Text] [Related]
40. Medication-related osteonecrosis of the jaw after once-a-year intravenous zoledronic acid infusion for osteoporosis: Report of eight cases. Favia G; Tempesta A; Limongelli L; Crincoli V; Maiorano E Quintessence Int; 2016; 47(5):433-40. PubMed ID: 26665262 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]